In postmenopausal women, 4 months of transdermal estradiol did not change the body's own oxytocin levels in peripheral blood or bone marrow plasma versus no treatment.
In plain wordsIn postmenopausal women, estrogen treatment did not change the body's own oxytocin levels compared with no treatment.
- Peptide
- Oxytocin
- Outcome
- No significant changePeripheral blood and bone marrow plasma oxytocin levels
- Study
n = 32
- Comparator
- No treatment
- Outcome group
- Sex hormones and fertility · Musculoskeletal
Source sentences
None of the peripheral blood or bone marrow plasma marker levels differed between the two groups
2 context sentences(design, population, supporting numbers)
as well as serotonin, OPG, RANKL, adiponectin, oxytocin, and inflammatory cytokines (TNFα, IL-1β, and IL-6)
Thus, we assessed the effects of 4months of transdermal estradiol treatment (0.05mg/day) of postmenopausal women as compared to no treatment (n=16 per group) on the expression of genes in pre-specified pathways in freshly isolated bone marrow osteoprogenitor cells (hematopoietic lineage [lin]-/Stro1+).
This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.